|
Home : Unsafe Drugs : Vytorin : Law Articles : Merck Agrees to Pay $41.5 Million in Vytorin Class Action Lawsuit Merck Agrees to Pay $41.5 Million in Vytorin Class Action LawsuitMerck Agrees to pay $41.5 million in Vytorin Class Action LawsuitThe makers of the popular cholesterol drugs, Vytorin and Zetia, have agreed to pay $41.5 million in a Vytorin class action lawsuit. Merck and Schering-Plough were accused of withholding unfavorable study results about the pharmaceutical blockbusters, Vytorin and Zetia, which showed that the drugs were not as effective at unclogging arteries as other less expensive alternatives. The study - completed almost two years prior to the release date - is one of several recent studies that has questioned the effectiveness of the drugs. The Downfall of a Pharmaceutical Giant?Several studies in the last two years have shown that a Niacin, a prescription of a common B vitamin, is far better at unclogging arteries than ezetimibe, the active ingredient in Zetia and Vytorin, at a substantially cheaper cost to the consumer. This comes as quite a blow to Vytorin, which combined with the sales of its sister drug Zetia, has raked in an astonishing $21 billion worldwide since 2003, according to the Securities and Exchange Commission. Do You Need Legal Advice Concerning Vytorin?Oftentimes, patients pursue a Vytorin lawsuit to seek monetary compensation to cover medical treatments due to cardiovascular complications. If you or a loved one has questions regarding a potential Vytorin Law suit, you may contact one of our experienced Vytorin Law firms. A Vytorin Lawyer can provide you with updates on Vytorin Side Effects, Vytorin-Cancer links or a possible Vytorin Recall. Contact a Vytorin Attorney using the form at the top of the page.
|




